Preclinical study Early signal Three groups of 12 mice: wild-type, untreated APP/PS1, and cordycepin-treated APP/PS1
Cordycepin changed microglial metabolism and memory behavior in an Alzheimer's mouse model
Purified cordycepin changed memory behavior and tissue markers in APP/PS1 mice. Experiments in BV2 and primary microglial cells linked the response to increased glycolysis through HKII and increased PDH-mediated oxidative phosphorylation through PDK2. The paper describes HKII and PDK2 as potential targets and notes that binding hypotheses need further verification. This animal-and-cell study does not demonstrate human treatment efficacy or support claims for whole Cordyceps supplements.
- What was studied
- Purified cordycepin at 10 mg/kg/day by gavage for four weeks; not a Cordyceps mushroom supplement
- Setting
- Studied alone
- Why it ranks here
- The study combines behavioral and mechanistic assays, but it remains one small animal experiment using purified cordycepin and has no human clinical outcome.
Limits and cautions
- The main efficacy experiment used 36 mice, and several tissue assays used only three animals per group.
- APP/PS1 mouse behavior and induced cell models do not establish efficacy or safety in humans with Alzheimer's disease.
- The intervention was purified cordycepin, not Cordyceps militaris, Ophiocordyceps sinensis, a fermentation product, or a retail supplement.
- The paper identifies HKII and PDK2 as potential molecular targets using localization, inhibitor, and metabolic assays; the proposed direct binding modes are hypotheses that the authors state require further verification.
- The authors reported no conflict of interest and public research funding; those statements do not substitute for independent replication.
Cordycepin and Cordyceps supplements are not FDA-approved to prevent or treat Alzheimer's disease or cognitive impairment.